Claudine Isaacs

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  3. pmc Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
    Eitan Friedman
    The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Breast Cancer Res 8:R15. 2006
  4. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
  5. pmc Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk
    Luisel J Ricks-Santi
    Howard University Cancer Center, 2041 Georgia Ave, NW Washington, DC 20060, USA
    BMC Cancer 11:278. 2011
  6. pmc Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
    Federico Canzian
    German Cancer Research Center DKFZ, Heidelberg, Germany
    BMC Cancer 9:257. 2009
  7. ncbi request reprint Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer
    Claudine Isaacs
    Department of Medical Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007 2197, USA
    Breast Cancer Res Treat 71:103-12. 2002
  8. ncbi request reprint A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients
    Claudine Isaacs
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, 20057, USA
    Breast Cancer Res Treat 93:125-34. 2005
  9. pmc Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
    Claudine Isaacs
    Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, Washington, DC 20057, USA
    Breast Cancer Res Treat 125:137-43. 2011
  10. pmc BRCA1/2 test results impact risk management attitudes, intentions, and uptake
    Suzanne C O'Neill
    Cancer Control Program and Fisher Center for Familial Cancer Research, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Breast Cancer Res Treat 124:755-64. 2010

Research Grants

  1. CANCER GENETICS NETWORK
    Claudine Isaacs; Fiscal Year: 2006

Detail Information

Publications77

  1. pmc Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
    Antonis C Antoniou
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
    Breast Cancer Res 14:R33. 2012
    ..2)...
  2. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  3. pmc Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
    Eitan Friedman
    The Suzanne Levy Gertner Oncogenetics Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Breast Cancer Res 8:R15. 2006
    ....
  4. pmc Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
    Susan L Neuhausen
    Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    Breast Cancer Res 11:R76. 2009
    ..In this study, we investigate the association of variants in genes involved in IGF signaling and risk of breast cancer in women who carry deleterious BRCA1 and BRCA2 mutations...
  5. pmc Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk
    Luisel J Ricks-Santi
    Howard University Cancer Center, 2041 Georgia Ave, NW Washington, DC 20060, USA
    BMC Cancer 11:278. 2011
    ..Here, we explore the relationships between the MSA and the Rad51 gene, which encodes a DNA repair enzyme that interacts with BRCA1 and BRCA2, in BRCA1 mutation carriers and women with sporadic breast cancer...
  6. pmc Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
    Federico Canzian
    German Cancer Research Center DKFZ, Heidelberg, Germany
    BMC Cancer 9:257. 2009
    ..We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3)...
  7. ncbi request reprint Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer
    Claudine Isaacs
    Department of Medical Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007 2197, USA
    Breast Cancer Res Treat 71:103-12. 2002
    ..These findings indicate a need for better education about screening guidelines for high-risk women...
  8. ncbi request reprint A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients
    Claudine Isaacs
    Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, 20057, USA
    Breast Cancer Res Treat 93:125-34. 2005
    ..This Phase III randomized multicenter trial compared progression-free (PFS) and overall survival (OS) for autologous peripheral blood stem cell (aPBSC) transplantation with or without immunotherapy in high-risk breast cancer patients...
  9. pmc Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
    Claudine Isaacs
    Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, Washington, DC 20057, USA
    Breast Cancer Res Treat 125:137-43. 2011
    ..Toxicities occurred frequently resulting in a high rate of discontinuation...
  10. pmc BRCA1/2 test results impact risk management attitudes, intentions, and uptake
    Suzanne C O'Neill
    Cancer Control Program and Fisher Center for Familial Cancer Research, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Breast Cancer Res Treat 124:755-64. 2010
    ..001). Receipt of BRCA1/2 mutation test results impacts how carriers see the positive aspects of RRO and RRM and their surgical intentions. Both the positive and negative aspects predict uptake of surgery...
  11. ncbi request reprint Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients
    Marc D Schwartz
    Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University School of Medicine, Suite 317, 2233 Wisconsin Avenue, Northwest, Washington, DC 20007, USA
    Cancer Epidemiol Biomarkers Prev 14:1003-7. 2005
    ..In this study, we evaluated factors associated with the decision to undergo BRCA1/BRCA2 gene testing at the time of initial breast cancer diagnosis...
  12. pmc Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance
    Marc D Schwartz
    Department of Oncology, Cancer Control Program, Jess and Mildred Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Cancer 118:510-7. 2012
    ..We evaluated long-term uptake and predictors of risk-reducing mastectomy (RRM), risk-reducing bilateral salpingo-oophorectomy (RRBSO), chemoprevention, and cancer screening among women at a mean of 5.3 years after testing...
  13. ncbi request reprint Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients
    Marc D Schwartz
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    J Clin Oncol 22:1823-9. 2004
    ..In the present study, we prospectively evaluated the impact on surgical decision-making of pretreatment genetic counseling and BRCA1/BRCA2 testing among breast cancer patients at high-risk for carrying a mutation...
  14. ncbi request reprint Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing
    Beth N Peshkin
    Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
    Cancer Epidemiol Biomarkers Prev 11:1115-8. 2002
    ..Noncarriers had very good adherence to general population screening guidelines...
  15. pmc Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction
    Marc D Schwartz
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Health Psychol 28:11-9. 2009
    ..To help BRCA1/2 carriers make this decision, the authors developed a computer-based interactive decision aid that was tested against usual care in a randomized controlled trial...
  16. ncbi request reprint Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing
    Marc D Schwartz
    Department of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC 20007, USA
    J Clin Oncol 21:4034-41. 2003
    ..In this study, we prospectively examined the impact of BRCA1/2 testing on the utilization of prophylactic oophorectomy and ovarian cancer screening. Participants and..
  17. ncbi request reprint Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer
    Luciane R Cavalli
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Genet Cytogenet 149:38-43. 2004
    ..Our results suggest that there is a field effect of early genetic events preceding morphologic changes in the mammary glands of BRCA mutation carriers...
  18. ncbi request reprint A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity
    Vered Stearns
    Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Clin Cancer Res 10:8332-40. 2004
    ..We chose tamoxifen to establish proof of principal with a known effective agent...
  19. pmc Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors
    Kristi D Graves
    Cancer Control Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Breast Cancer Res Treat 104:321-9. 2007
    ..To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in addition to mastectomy of the affected breast...
  20. ncbi request reprint Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing
    Kenneth P Tercyak
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007 2401, USA
    J Clin Oncol 25:285-91. 2007
    ..In this study, we compared the impact of BRCA1/2 genetic test result and CPM on these outcomes among newly diagnosed breast cancer patients who opted for CPM at the time of their definitive surgical treatment versus patients who did not...
  21. ncbi request reprint Management updates for women with a BRCA1 or BRCA2 mutation
    Rachel Nusbaum
    Lombardi Comprehensive Cancer Center, Jess and Mildred Fisher Center for Familial Cancer Research, Washington, DC, USA
    Mol Diagn Ther 11:133-44. 2007
    ..Currently, BRCA carrier status is not used as an independent prognostic factor regarding systemic treatment options...
  22. pmc Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901
    Jeanne S Mandelblatt
    Lombardi Comprehensive Cancer Center, 3300 Whitehaven Blvd, Washington, DC 20007, USA
    J Clin Oncol 30:2609-14. 2012
    ..It will be important to re-evaluate the impact of decision styles when there is greater empirical evidence about the benefits and risks of chemotherapy in older patients...
  23. pmc Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice
    Kristi D Graves
    Department of Oncology, Cancer Control Program, Breast Cancer Program, Jess and Mildred Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Washington, District of Columbia 20007, USA
    Cancer Epidemiol Biomarkers Prev 21:445-55. 2012
    ..We conducted the first long-term prospective study of psychosocial outcomes in a U.S. sample of women who had BRCA1/2 testing...
  24. doi request reprint Perceived risk of breast cancer among Latinas attending community clinics: risk comprehension and relationship with mammography adherence
    Kristi D Graves
    Department of Oncology, Cancer Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20007, USA
    Cancer Causes Control 19:1373-82. 2008
    ..To describe breast cancer risk perceptions, determine risk comprehension, and evaluate mammography adherence among Latinas...
  25. ncbi request reprint Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians
    Beth N Peshkin
    CGC, 2233 Wisconsin Ave, NW, Suite 317, Washington, DC 20007, USA
    J Clin Oncol 21:4322-8. 2003
    ..To assess physician recommendations about the use of tamoxifen in premenopausal BRCA1 and BRCA2 mutation carriers...
  26. ncbi request reprint Predictors of enrollment into a familial cancer registry by individuals at high risk for BRCA1/2
    Kristi D Graves
    Cancer Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, 3300 Whitehaven Street, Northwest, Suite 4100, Washington, DC 20007, USA
    Cancer Epidemiol Biomarkers Prev 16:2763-7. 2007
    ..We also sought to identify the factors associated with provision of a blood sample to the FCR...
  27. ncbi request reprint Evaluation and management of women with BRCA1/2 mutations
    Beth N Peshkin
    Oncology and Medicine Department of Cancer Control, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC, USA
    Oncology (Williston Park) 19:1451-9; discussion 1459-68 1474. 2005
    ..We conclude with a review and appraisal of the various options for breast and ovarian cancer risk reduction and screening options for women with a BRCA1 or BRCA2 mutation...
  28. ncbi request reprint Practical aspects of delivering hereditary cancer risk counseling
    Tiffani A Demarco
    Jess and Mildred Fisher Center for Familial Cancer Research, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Semin Oncol 34:369-78. 2007
    ....
  29. ncbi request reprint Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
    Vered Stearns
    Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
    J Clin Oncol 23:6919-30. 2005
    ..A secondary objective was to evaluate quality of life (QOL) parameters...
  30. pmc Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives
    Elizabeth Spellman
    Lombardi Comprehensive Cancer Center, Washington, DC, USA
    Psychooncology 22:2110-6. 2013
    ..This study sought to examine medical and surgical oncologists' perceptions of factors related to the translation and integration of Oncotype DX® (Genomic Health, Inc., Redwood City, CA, USA) into routine clinical care...
  31. ncbi request reprint Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample
    Marc D Schwartz
    Department of Oncology, Georgetown University, and Lombardi Cancer Center, Washington, DC 20007, USA
    J Clin Oncol 20:514-20. 2002
    ..The objective of this study was to examine the long-term psychologic impact of receiving BRCA1/2 test results within a clinic-based testing program...
  32. doi request reprint Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007 2198, USA
    J Clin Oncol 27:5153-9. 2009
    ..We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging...
  33. ncbi request reprint Utilizing prognostic and predictive factors in breast cancer
    Deepa S Subramaniam
    Georgetown University Medical Center, Lombardi Cancer Center, 3800 Reservoir Road, Washington, DC 20007, USA
    Curr Treat Options Oncol 6:147-59. 2005
    ..Therefore, new data must be interpreted with caution...
  34. pmc Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship
    Vanessa B Sheppard
    Breast Cancer Program, Lombardi Comprehensive Cancer Center and Department of Oncology, Georgetown University, 3300 Whitehaven St NW, Suite 4100, Washington, DC 20007, USA
    Breast Cancer Res Treat 139:207-16. 2013
    ..8.3 %; p = 0.024), but this was not significant after considering religiosity. The patient-physician dyad and sociocultural factors may represent leverage points to improve chemotherapy patterns in black women...
  35. pmc Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS
    Nadiyah Sulayman
    Department of Oncology, The Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC 20007, USA
    J Cancer Epidemiol 2012:728290. 2012
    ..These data should be confirmed in prospective samples, as these poorer outcomes could be amenable to intervention...
  36. pmc Providers' perceptions and practices regarding BRCA1/2 genetic counseling and testing in African American women
    Kristi D Graves
    Lombardi Comprehensive Cancer Center, Cancer Control Program, Fisher Center for Familial Cancer Research, Georgetown University, Washington, DC 20007, USA
    J Genet Couns 20:674-89. 2011
    ..Results have implications for physician and patient education regarding appropriate referrals to and uptake of genetic services in at-risk African American women...
  37. doi request reprint BRCA1/2 mutations and triple negative breast cancers
    Beth N Peshkin
    Fisher Center for Familial Cancer Research, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC 20007 2401, USA
    Breast Dis 32:25-33. 2010
    ..Identifying women at increased risk is critical as knowledge of mutation status may impact surgical and systemic treatment in newly diagnosed patients, as well as recommendations for ovarian cancer risk management...
  38. pmc Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians
    Jeanne S Mandelblatt
    Georgetown University School of Medicine and Lombardi Comprehensive Cancer Center, Washington, DC, USA
    J Clin Oncol 28:3146-53. 2010
    ..Breast cancer chemotherapy decisions in patients > or = 65 years old (older) are complex because of comorbidity, toxicity, and limited data on patient preference. We examined relationships between preferences and chemotherapy use...
  39. doi request reprint Prediction of benefit from adjuvant treatment in patients with breast cancer
    Jennifer Eng-Wong
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007 2113, USA
    Clin Breast Cancer 10:E32-7. 2010
    ..This concept is currently being evaluated in multiple well-designed clinical trials...
  40. ncbi request reprint Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients
    Claudine Isaacs
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
    Breast Cancer Res Treat 84:99-105. 2004
    ..One NAF sample from a BRCA1 patient showed a mtDNA mutation. Our data demonstrates the feasibility of performing molecular studies using the free DNA present in the ductal fluid, while the intact cells can be used for cytologic studies...
  41. pmc BRCA mutation testing in determining breast cancer therapy
    Karen Lisa Smith
    Department of Medicine, Division of Hematology and Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Cancer J 17:492-9. 2011
    ..In addition, the sensitivity of BRCA mutation-associated breast cancer to endocrine therapy, platinum chemotherapy, and poly (ADP-ribose) polymerase inhibitors is reviewed...
  42. ncbi request reprint Venous thromboembolic disease and stroke in women taking tamoxifen for breast cancer chemoprevention
    Claudine Isaacs
    Clinical Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, USA
    Clin Adv Hematol Oncol 3:913-4. 2005
  43. ncbi request reprint A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer
    Vered Stearns
    Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Clin Cancer Res 9:124-33. 2003
    ....
  44. ncbi request reprint Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    J Clin Oncol 22:1055-62. 2004
    ..Thus, we estimated the degree of breast cancer risk reduction after surgery in women who carry these mutations...
  45. ncbi request reprint A comparison of bilateral breast cancers in BRCA carriers
    Jeffrey N Weitzel
    The Centre for Research in Women s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8
    Cancer Epidemiol Biomarkers Prev 14:1534-8. 2005
    ..It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown...
  46. ncbi request reprint Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers
    Carey A Cullinane
    City of Hope National Medical Center, Duarte, CA, USA
    Int J Cancer 117:988-91. 2005
    ..Among BRCA2 carriers, increasing parity was associated with a significant increase in the risk of breast cancer before age 50 and this increase was greatest in the 2-year period following a pregnancy...
  47. ncbi request reprint Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers
    Andre Nkondjock
    Epidemiology Research Unit, Research Centre, Centre Hospitalier de Universitaire de Montréal, CHUM Hotel Dieu, Montreal, Canada
    Int J Cancer 118:103-7. 2006
    ..These results suggest that among women with BRCA gene mutation, coffee consumption is unlikely to be harmful and that high levels of consumption may in fact be related to reduced breast cancer risk...
  48. ncbi request reprint The Cancer Genetics Network: recruitment results and pilot studies
    Hoda Anton-Culver
    Epidemiology Division, College of Medicine, University of California, Irvine, 92697 7550, USA
    Community Genet 6:171-7. 2003
    ....
  49. ncbi request reprint Cancer variation associated with the position of the mutation in the BRCA2 gene
    Jan Lubinski
    Hereditary Cancer Center Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland
    Fam Cancer 3:1-10. 2004
    ..0; P = 0.03) compared to families of other ethnic origins. In conclusion, both the position of mutation and the ethnic background of the family appear to contribute to the phenotypic variation observed in families with BRCA2 mutations...
  50. ncbi request reprint Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study
    Andrea Eisen
    Toronto Sunnybrook Regional Cancer Center, Toronto, ON, Canada
    J Clin Oncol 23:7491-6. 2005
    ....
  51. pmc Characterization of BRCA1 and BRCA2 mutations in a large United States sample
    Sining Chen
    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Clin Oncol 24:863-71. 2006
    ..Existing studies have focused on Ashkenazi Jews (AJ) or on families from outside the United States. In this article, we consider the US population using the largest US-based cohort to date of both AJ and non-AJ families...
  52. ncbi request reprint Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Steven A Narod
    The Centre for Research on Women s Health, University of Toronto, 790 Bay Street, Toronto, Ontario M5G 1N8, Canada
    J Natl Cancer Inst 94:1773-9. 2002
    ..We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2...
  53. ncbi request reprint Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
    N Engl J Med 346:1616-22. 2002
    ..We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations...
  54. ncbi request reprint All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results
    Chanita Hughes
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Med Genet 107:143-50. 2002
    ....
  55. ncbi request reprint Smoking and the risk of breast cancer among carriers of BRCA mutations
    Parviz Ghadirian
    Epidemiology Research Unit, Centre Hospitalier del Universite de Montreal Hotel Dieu, Faculty of Medicine, Universite de Montreal, Montreal, Quebec, Canada
    Int J Cancer 110:413-6. 2004
    ..03; 95% CI 0.83 to l.28) or before the first pregnancy (OR = 1.09; 95% CI = 0.90 to 1.33). In conclusion, contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations...
  56. pmc Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
    Andrea Eisen
    Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
    J Natl Cancer Inst 100:1361-7. 2008
    ....
  57. ncbi request reprint Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, University of Toronto, Women s College Hospital, 790 Bay Street, 7th Floor, Totonto, Ontario M5G 1N8, Canada
    Cancer Causes Control 16:667-74. 2005
    ..46; 95% CI 0.30-0.69). This study implicates early age at menarche as a determinant of breast cancer among women with a BRCA1 mutation...
  58. ncbi request reprint Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study
    Constance D Lehman
    Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, G3 200, Seattle, WA 98109 1023, USA
    Radiology 244:381-8. 2007
    ..To prospectively determine cancer yield, callback and biopsy rates, and positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, and ultrasonography (US) in women at high risk for breast cancer...
  59. pmc AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
    Fergus J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:1416-21. 2007
    ..In summary, the F31I polymorphism in AURKA is not associated with a modified risk of breast cancer in BRCA1 and BRCA2 carriers...
  60. pmc Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Toronto, ON, Canada
    Breast Cancer Res 7:R833-43. 2005
    ..We asked whether there is an association between changes in body weight and the risk of breast cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or BRCA2...
  61. ncbi request reprint Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, Women s College Hospital, University of Toronto, Room 750, 790 Bay Street, 7th Floor, Toronto, ON M5G 1N8, Canada
    Breast Cancer Res Treat 105:221-8. 2007
    ..Nonetheless, BRCA mutation carriers opting for a prophylactic oophorectomy as a breast and/or ovarian cancer risk-reducing strategy should complete childbearing prior to age 40 when this prevention modality is most effective...
  62. ncbi request reprint Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    J Clin Oncol 23:7804-10. 2005
    ..Thus, we evaluated whether the breast cancer risk reduction conferred by BPO in BRCA1/2 mutation carriers is altered by use of post-BPO HRT...
  63. ncbi request reprint Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study
    Susan M Domchek
    Abramson Cancer Centre, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Lancet Oncol 7:223-9. 2006
    ..However, the reduction in mortality after this surgery is unclear. We aimed to assess whether BPSO improves overall mortality or cancer-specific mortality in BRCA1 and BRCA2 mutation carriers...
  64. ncbi request reprint Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
    Steven A Narod
    Centre for Research on Women s Health, University of Toronto, Ontario, Canada
    Lancet Oncol 7:402-6. 2006
    ..We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers...
  65. ncbi request reprint Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer
    Lori J Pierce
    Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109 0010, USA
    J Clin Oncol 24:2437-43. 2006
    ..We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation carriers with breast cancer versus that of matched sporadic controls...
  66. pmc Validity of models for predicting BRCA1 and BRCA2 mutations
    Giovanni Parmigiani
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
    Ann Intern Med 147:441-50. 2007
    ..At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood...
  67. ncbi request reprint Management of women at increased risk for hereditary breast cancer
    Karen Lisa Smith
    Washington Cancer Institute, Washington Hospital Center, Washington DC 20010, USA
    Breast Dis 27:51-67. 2006
    ..Finally, the management of women at risk for hereditary breast cancer in whom deleterious mutations are not identified is reviewed...
  68. doi request reprint Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers
    Tara M Friebel
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Clin Breast Cancer 7:875-82. 2007
    ..The availability of these risk-reduction strategies is an important consideration in the decision to undergo genetic testing...
  69. pmc RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
    Am J Hum Genet 81:1186-200. 2007
    ..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers...
  70. ncbi request reprint Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Joanne Kotsopoulos
    Centre for Research in Women s Health, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1N8
    Gynecol Oncol 100:83-8. 2006
    ..This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers...
  71. doi request reprint Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group
    Kelly A Metcalfe
    Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada
    J Clin Oncol 26:1093-7. 2008
    ..To evaluate the rate of prophylactic contralateral mastectomy in an international cohort of women with hereditary breast cancer and to evaluate the predictors of uptake of preventive surgery...
  72. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  73. pmc Rapid progression of prostate cancer in men with a BRCA2 mutation
    S A Narod
    Women s College Research Institute, 790 Bay Street, 7th Floor, Women s College Hospital, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 99:371-4. 2008
    ..0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation...
  74. pmc Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    Am J Hum Genet 82:937-48. 2008
    ....
  75. ncbi request reprint Breast cancer-related pseudocirrhosis and esophageal varices
    Veena Chandrakar
    Breast J 11:301-2. 2005
  76. ncbi request reprint The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
    P Kelly Marcom
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
    Breast Cancer Res Treat 102:43-9. 2007
    ..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study...
  77. ncbi request reprint Analysis of co-aggregation of cancer based on registry data
    Abigail G Matthews
    Massachusetts General Hospital Biostatistics Center, Boston, MA 02114, USA
    Community Genet 9:87-92. 2006
    ..An exploratory analysis of co-aggregation of cancers using registry-based data...

Research Grants2

  1. CANCER GENETICS NETWORK
    Claudine Isaacs; Fiscal Year: 2006
    ....